The editorial specifically cites three Japanese cases: young women aged 21 to 23, none with diabetes and two not classified as obese, hospitalized with ketosis or ketoacidosis after using tirzepatide inappropriately — in two cases, the reaction occurred at the lowest starting dose. The authors note that many of these cases involved people acquiring the medication, prescribed and reimbursed in Japan specifically for type 2 diabetes, through unofficial channels for cosmetic weight loss instead, sometimes combined with aggressive dieting on top of the drug’s own appetite-suppressing effects.
Similar cases have surfaced elsewhere. A case report published in JCEM Case Reports described a 23-year-old Japanese woman who developed ketoacidosis after obtaining tirzepatide through an aesthetic clinic without ongoing medical supervision. In the UK, a case published in Cureus described a 48-year-old woman who developed the same complication after starting tirzepatide through an online prescription; she recovered after hospital treatment and was advised to stop the medication and seek supervised weight management going forward. Separately, UK researchers have estimated that as many as 500,000 people may currently be using GLP-1 drugs like Mounjaro or Wegovy through private online prescriptions rather than standard medical channels — a scale that helps explain why oversight gaps are drawing growing concern.
The Bigger Argument Behind the Warning
The editorial’s authors make a broader point worth understanding: they argue that “appropriate” GLP-1 use shouldn’t be judged only by whether a prescription is technically legal, but by whether the weight loss it produces is medically safe, nutritionally adequate, and properly supervised. Their assessment is notably measured — they suggest much of the harm reflects unsafe weight-loss practices generally (severe caloric restriction, lack of monitoring) layered on top of the drug’s effects, rather than proving the drugs themselves are inherently more dangerous than understood. Separate research has also linked GLP-1 drugs to reduced lean muscle mass and, when discontinued, a tendency for regained weight to be primarily fat rather than muscle — underscoring that supervised, structured use matters throughout treatment, not just at the point of prescribing.
What This Means for You
For Complete Cooking STEPS Please Head On Over To Next Page Or Open button (>) and don’t forget to SHARE with your Facebook friends.
